The New Era of Targeted Genomic Medicine in Europe

Europe is pioneering precise gene therapy by advancing targeted delivery—using engineered viral vectors, smart nanoparticles, and AI-driven design—to enable safer, more effective, and highly localised genetic treatments.

Life Sciences Review | Monday, March 02, 2026

Genomic medicine in Europe has moved from proving gene replacement is possible to refining delivery methods. As the European Medicines Agency (EMA) streamlines pathways for advanced therapy medicinal products (ATMPs), researchers are addressing the delivery challenge: guiding therapeutic agents to precise molecular targets in the body.

This era of molecular precision is marked by a shift from broad, systemic treatments to targeted, cell-specific interventions. Leveraging strong research infrastructure in countries such as Germany, France, and the Netherlands, scientists are expanding the potential of genetic therapies through improved delivery methods.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Evolutionary Architectures in Viral Vector Engineering

Current innovation focuses on the directed evolution of viral capsids, the protein shells that carry genetic material, to enhance their ability to navigate the human body. A significant development in this field is the introduction of capsid shuffling technologies, pioneered by European research consortia. This method recombines genetic sequences from various viral strains, such as different adeno-associated virus (AAV) serotypes, to create large libraries of unique capsid variants. High-throughput molecular screening then identifies candidates with strong, selective affinity for specific organs or cell types, such as the heart, liver, or central nervous system. Through repeated selection cycles, viral envelopes are refined to avoid non-target tissues and improve delivery to intended sites.

Advances in transcriptional control further improve precision in gene therapy. Beyond guiding vector localisation, modern European delivery platforms now regulate therapeutic gene expression. This is accomplished using synthetic promoters, which are laboratory-engineered DNA sequences that act as highly selective molecular switches. Unlike conventional promoters that may activate gene expression in all transduced cells, synthetic promoters are designed to respond only to specific transcription factors found in the target cell population, such as defined neuronal subtypes or cardiomyocytes.

These innovations create a dual layer of precision in gene delivery. Engineered capsids with tissue-specific tropism provide physical targeting, while synthetic promoters enable functional targeting through transcriptional regulation. This integrated approach significantly reduces off-target effects and confines therapeutic activity to the intended biological context, establishing a mature and highly controlled paradigm for viral vector–based gene delivery in Europe.

Synthetic Nanoparticle Innovation and Extra-Hepatic Targeting

Viral vectors remain the standard for durable gene expression, but non-viral delivery platforms, especially lipid nanoparticles (LNPs) and polymer-based carriers, have advanced rapidly in Europe’s biotechnology sector. A key research focus has been achieving reliable extra-hepatic delivery to target tissues beyond the liver, which is the typical accumulation site for many nanoparticle systems.

Conventional LNPs are effective but tend to accumulate in the liver due to interactions with blood proteins. To address this, European researchers are developing strategies for surface functionalization. By modifying nanoparticle surfaces with engineered molecular ligands such as monoclonal antibodies, aptamers, or targeting peptides, these systems can be directed to specific cellular receptors. This enables selective uptake by non-hepatic tissues, including the lungs, bone marrow, and other clinically relevant targets.

Significant progress has been made in advanced polymeric and hybrid delivery systems. Mature technologies such as polymersomes and dendrimers now offer greater structural stability and increased cargo capacity. These features are especially beneficial for delivering complex genetic payloads, including large RNA constructs and gene-editing systems such as CRISPR-Cas9. Hybrid platforms that combine lipid biocompatibility with polymer rigidity are being optimised to enhance endosomal escape, a critical process that enables therapeutic cargo to reach the cytoplasm before cellular degradation.

Compared to viral vectors, non-viral systems offer distinct advantages. Viral vectors are limited by capsid size, which restricts cargo capacity, and depend on capsid engineering or promoter selection for targeting. Their main advantage is long-term gene expression, making them preferred for neurological and muscle disorders in European research. In contrast, non-viral platforms provide flexible payload capacity, precise targeting through chemical tuning and surface ligands, and support for repeat dosing with a lower immune response. As a result, European development in non-viral delivery is increasingly focused on oncology and systemic RNA-based therapies.

Stimuli-Responsive and Bio-Hybrid Molecular Systems

Gene therapy delivery in Europe is advancing through the development of intelligent carrier systems. These platforms go beyond passive transport and actively respond to the molecular characteristics of specific disease environments. They are designed to improve therapeutic precision by releasing genetic material only under defined pathological conditions, thereby increasing efficacy and reducing off-target effects.

A key group of these technologies includes smart, stimuli-responsive carriers engineered to detect and respond to physical or chemical cues in diseased tissues. In many pathological conditions, local factors such as pH or enzyme concentration differ significantly from those in healthy tissue. European research groups have developed nanoparticle carriers that remain stable and inactive in the bloodstream at physiological pH (~7.4), but change structure when exposed to acidic environments found in tumours or inflamed joints (pH < 6.5). This targeted activation allows for controlled release of genetic payloads at the disease site.

At the same time, significant advances have been made in developing bio-hybrid delivery platforms, including exosomes and virus-like particles (VLPs). Exosomes are naturally occurring extracellular vesicles secreted by cells, offering inherent biocompatibility and the ability to facilitate cellular communication. VLPs are made of viral structural proteins but lack viral genetic material, making them non-infectious while maintaining efficient cell entry. Using advanced biomanufacturing in European facilities, scientists produce these carriers with specialised cell lines, balancing the delivery efficiency of viral systems with the safety of synthetic nanoparticles.

The integration of AI and ML in molecular and delivery system design is accelerating innovation. European laboratories now use AI-driven models to predict interactions between capsid protein sequences and human cell receptors and to simulate the in vivo behaviour of lipid or polymer formulations. This in silico approach shortens development timelines and enables rapid optimisation of delivery vehicles before experimental validation. These advances are driving a new generation of gene therapies that are more precise, efficient, and tailored to the complexity of human disease.

The move toward molecular precision in Europe marks a fundamental shift in medical philosophy. By refining gene delivery methods, the industry is advancing toward highly localised and controlled genetic interventions.

More in News

Pharmaceutical Compliance in a Serialized Supply Chain

Pharmaceutical compliance has moved beyond recordkeeping into the daily movement of product, data and accountability across the supply chain. For manufacturers, wholesale distributors and third-party logistics providers, compliance now depends on whether each package can be identified, verified, traced and reported without forcing teams to reconcile disconnected systems. The pressure is not only regulatory. Counterfeit risk, expired product control, trading partner accuracy and audit readiness all sit inside the same business workflow. A strong compliance platform must bring those demands together without turning compliance into a parallel process that slows commercial activity or leaves leaders dependent on fragmented reports. The most reliable solutions are built around traceability at the transaction level. Serialization cannot be treated as a late-stage attachment to inventory management because the value of a serial number depends on how consistently it travels through purchasing, receiving, sales, returns, financial records and partner exchange. When serialization lives outside the system that manages the business, companies often inherit duplicate entries, timing gaps and inconsistent product data. Those weaknesses become expensive when regulators require proof, customers request verification or leadership needs a clean view of inventory exposure. A better system keeps compliance evidence close to the events that create it, allowing teams to act from the same source of truth rather than comparing data after problems appear. Executives should also look closely at how a platform handles reporting and exception management. Pharma teams need systems that can capture required data, generate reports and support Drug Supply Chain Security Act obligations without relying on manual workarounds. The right solution should reduce dependence on extra staffing for routine tasks, give teams timely visibility into product status and help prevent expired or suspect products from moving forward. Compliance technology should not simply store information. It should make the right information available when a trading partner, regulator or internal leader needs it. That level of discipline becomes especially important for companies operating across multiple states, serving many customers or managing products whose lifecycle data must remain accurate from receipt to distribution. Data protection has become equally central because cloud-based compliance systems hold commercially sensitive information about product movement, customers, orders and financial activity. Encryption, network security, threat detection and compliance controls are no longer supporting features. They are part of the decision. Executives need confidence that the platform protects proprietary data while still enabling authorized users to work across sites, functions and partners. Scalability also matters because pharmaceutical companies rarely remain static. License expansion, new partner relationships, added states, higher transaction volume and broader service lines can quickly expose whether a system was designed for growth or merely configured for a current process. “ For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. “ This is where RxERP stands out as the premier choice for pharmaceutical organizations that need compliance embedded into core business execution rather than added around it. Its platform combines ERP functionality with automated serialization, traceability, reporting, inventory, finance, CRM and business intelligence for manufacturers, distributors and third-party logistics providers. The transcript points to a wholesaler and 3PL that replaced fragmented systems with one integrated platform, improving automation, reporting, data management and DSCSA compliance while achieving measurable financial and revenue gains. For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Specials

The New Era of Targeted Genomic Medicine in Europe

Europe is pioneering precise gene therapy by advancing targeted delivery—using engineered viral vectors, smart nanoparticles, and AI-driven design—to enable safer, more effective, and highly localised genetic treatments.